Analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Get Free Report) in a report issued on Thursday. The firm set a "hold" rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
NYSE:BTX opened at $6.27 on Thursday. The firm has a market cap of $368.84 million, a P/E ratio of -2.76 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $5.10 and a fifty-two week high of $8.31. The firm has a 50-day simple moving average of $6.38 and a two-hundred day simple moving average of $2.66.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
